
FDA Approves Lumvoa for Thyroid Eye Disease, Including Chronic Cases
The second IGF-1R antibody cleared for the condition extends targeted treatment to patients in both active and chronic stages, its developer says.
Drug approvals, product recalls, safety advisories and revised clinical guidance, written so a reader knows immediately whether it applies to them.

The second IGF-1R antibody cleared for the condition extends targeted treatment to patients in both active and chronic stages, its developer says.

Xocova (ensitrelvir) cut the risk of symptomatic infection by about 67 percent in the SCORPIO-PEP trial and is cleared for people 12 and older.

Eli Lilly's orforglipron delivered an average 12.4 percent weight loss at the highest dose in trials and can be taken without food or water restrictions.

The agency cleared copper histidinate injection, ending a decades-long stretch in which care for the rare copper-transport disorder was supportive only.